Publications and Patents

Highlight Publications

Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–like Antigen-Presenting Cells as Cancer Immunotherapy

Tianyi Liu, Dan Jin, Son B. Le, Dongjiang Chen, Mathew Sebastian, Alberto Riva, Ruixuan Liu, and David D. Tran (Cancer Immununol Res 2024)

AI-directed conversion of GBM to iDC is predicted to be much more efficient, compared to the inefficient, multi-stage iPSC/HSC-based conversion.
Machine-Learning-Directed-ConversionDownload

The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields

Dongjiang Chen, Son B. Le, Harshit Manektalia, Tianyi Liu, Tarun E. Hutchinson, Adam O’Dell, Bodour Salhia, and David D. Tran (Cancer Research 2024)

The nuclear EP3-ZNF488 axis drives GSC self-renewal and in vivo tumorigenicity, promotes resistance to TTFields, and represents a critical target for enhancing therapeutic efficacy.
Ep3-znf488-axisDownload

Publications

2024

  1. Chen, D, Le, SB, Hutchinson, TE, Liu, T, O’Dell, A, Salhia, B and Tran, DD. The EP3-ZNF488 Axis Regulates Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields. Cancer Res. 2024 Oct 16. https://doi.org/10.1158/0008-5472.CAN-23-3643
  2. Liu, T, Jin, D, Le, SB, Chen, D, Sebastian, M, Liu, R, and Tran, DD. Machine-learning Directed Conversion of Glioblastoma to Dendritic Cell-like Antigen Presenting Cells as Cancer Immunotherapy. Cancer Immunol Res. 2024. Jul 25. https://doi.org/10.1158/2326-6066.CIR-23-0721
  3. Chen, R, Rey, J, Tuna, I, Tran, DD, and Sarntinoranont, M. A spatial interpolation approach to assign MRI-derived material properties for finite element models of AAV infusion into a recurrent brain tumor. J Biomech Eng. 2024 Apr 6:1-50. doi: 10.1115/1.4064966. Online ahead of print. https://doi.org/10.1115/1.4064966

2023

  1. Liau, L, Ashkan, K, Brem, S, Campian, J, Trusheim, J, Iwamoto, F, Tran, DD, Ansstas, G, Cobbs, C, Heth, J, Salacz, M, D’Andre, S, Aiken, R, Moshel ,Y, Nam, JY, Pillainayagam, C, Wagner, S, Walter, K, Chaudhary, R, Goldlust, S, Lee, I, Bota, D, Elinzano, H, Grewal, J, Lillehei, K, Mikkelsen, T, Walbert, T, Abram, S, Brenner, A, Ewend, M, Khagi, S, Lovick, D, Portnow, J, Kim, L, Loudon, W, Martinez, N, Thompson, R, Avigan, D, Fink, K, Geoffroy, F, Giglio, P, Gligich, O, Krex, D, Lindhorst, S, Lutzky, J, Meisel, HJ, Nadji-Ohl, M, Sanchin, L, Sloan, A, Taylor, L, Wu, J, Dunbar, E, Etame, A, Kesari, S, Mathieu, D, Piccioni, D, Baskin, D, Lacroix, M, May, SA, New, P, Pluard, T, Toms, S, Tse, V, Peak, S, Villano, J, Battiste, J, Mulholland, P, Pearlman, M, Petrecca, K, Schulder, M, Prins, R, Boynton, A, Bosch, M (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA oncology, 9(1), 112–121. https://doi.org/10.1001/jamaoncol.2022.5370
  2. Ghiaseddin, AP, Ernster, AE, Body, A, Deleyrolle, P, St. Clair, J, Sampson, D, Bacharz, K, Yan, SC, Melnick, K, Allen, A, Rahman, M, Tran, D, Mitchell, D, Pereira, DB. Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors. J Neuro-Onc. 164(3):701-710. In press, 2023. PMID: 37804375, PMCID: PMC10695656 https://doi.org/10.1007%2Fs11060-023-04469-2
  3. Cheok, SK, Yu, C, Fen, JF, Briggs RG, Chow, F, Hwang, L, Je, J, Attenello, FJ, Tran, D, Chang, E, Zada, G (2023). Comparison of preoperative versus postoperative treatment dosimetry plans of single-fraction stereotactic radiosurgery for surgically resected brain metastases. Neurosurg. Focus. 55(2):E9. https://doi.org/10.3171/2023.5.focus23209

2022

  1. Chen, DJ, Le, SB, Hutchinson, TE, Calinescu, AA, Sebastian, M, Jin, D, Liu, TY, Ghiaseddin, A, Rahman, M, Tran, DD (2022). Tumor treating fields dually activate sting and aim2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest. 132(8):e159073. https://doi.org/10.1172/jci149258
  2. Melnick, KF, Miller, P, Carmichael, E,  McGrath K, Ghiaseddin, A, Tran, DD, Rahman, M (2022). The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival. J Neuro-Oncol, 159(2), 479–484. https://doi.org/10.1007/s11060-022-04083-8

2021

  1. Butt, OH, Zhou, AY, Huang, J, Chheda, MG, Johanns, T, Ansstas, G, Liu, J, Talcott, G, Nakiwala, R, Shimony, JS, Kim, AH, Leuthardt, EC*, Tran, DD*, Campian, JL* (2021). A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neuro-Oncol Adv. 4(1):vdac042. https://doi.org/10.1093/noajnl/vdab164. *Senior/corresponding author.
  2. Gatson, NTN, Barnholtz-Sloan, J, Drappatz, J, Henriksson, R, Hottinger, AF, Hinoul, P, Kruchko, C, Puduvalli, VK, Tran, DD, Wong, ET, Glas, M (2021). Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol, 11, 679702. https://doi.org/10.3389/fonc.2021.679702
  3. Shin, DH, Melnick, KF, Tran, DD, & Ghiaseddin, AP (2021). In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas. J Neuroonc. 151(1), 85–92. https://doi.org/10.1007/s11060-020-03557-x
  4. Melnick, K, Shin, D, Dastmalchi, F, Kabeer, Z, Rahman, M, Tran, DD, Ghiaseddin, A. Role of Laser Interstitial Thermal Therapy in the Management of Primary and Metastatic Brain Tumors. Curr Treat Options Oncol. 22 (12):108, 2021. PMID# 34687357.
  5. De Los Santos, Y, Shin, D, Malnik, S, Rivera-Zengotita, M, Tran, DD, Ghiaseddin, AP, Kresak, JL (2021). Intracranial myxoid mesenchymal neoplasms with EWSR1 gene rearrangement: report of 2 midline cases with one demonstrating durable response to MET inhibitor monotherapy. Neuro-Oncol. Adv. 3(1):vdab016. https://doi.org/10.1093/noajnl/vdab016

2020

  1. Reardon, DA, Desjardins, A, Vredenburgh, J, O’Rourke, DM; Tran, DD, Fink, KL, Nabors, LB, Gordon, L, DA, Bota, DA, Lukas, RV, Ashby, LS, Duic JP, Mrugala, MM, Cruickshank, S, Vitale, L, He, Y, Green, J, Yellin, MJ, Turner, CD, Keler, T, Davis, TA, Sampson, JH (2020). Rindopepimut with Bevacizumab for Patients with Relapsed EGFRviii-expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase 2 Trial. Clin. Cancer Res. 26(7):1586-1594. https://doi.org/10.1158/1078-0432.CCR-18-1140
  2. Puduvalli, VK, Wu, J, Yuan, Y, Armstrong, TS, Vera, E, Wu, J, Xu, J, Giglio, P, Colman, H, Walbert, T, Raizer, J, Groves, M, Tran, DD, Iwamoto, F, Avgeropoulos, N, Paleologos, N, Fink, K, Peereboom, D, Chamberlain, M, Merrell, R, Prado, MP, Yung, WKA, Gilbert, MR (2020). A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro-Oncol. 22(10):1505-1515. https://doi.org/10.1093/neuonc/noaa062
  3. Ghiaseddin, AP, Shin, D, Melnick, K, & Tran, DD (2020). Tumor Treating Fields in the Management of Patients with Malignant Gliomas. Current treatment options in oncology, 21(9), 76. https://doi.org/10.1007/s11864-020-00773-5

2019

  1. Galanis, E, Anderson, SK, Twohy, EL, Carrero, XW, Dixon, JG, Tran, DD, Jeyapalan, SA, Anderson, DM, Kaufmann, TJ, Feathers, RW, Giannini, C, Buckner, JC, Anastasiadis, PZ, Schiff, D (2019). A Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance NCCTG N0872. Cancer. 125(21):3790-3800. https://doi.org/10.1002/cncr.32340
  2. Morley, CD, Ellison, SV, Bhattacharjee, T, O’Bryan, CS, Zhang, Y, Smith, K, Kabb, CP, Sebastian, M, Moore GL, Schulze, KD, Niemi, S, Sawyer, WG, Tran, DD, Mitchell, D, Sumerlin, B, Flores, CT, Angelini, TE (2019). Quantitative Characterization of 3D Bioprinted Structural Elements under Cell Generated Forces. Nat. Comm. 10(1): 3029. https://doi.org/10.1038/s41467-019-10919-1
  3. Jin, D, Nguyen, N, and Tran, DD (2019). Combining CDK4/6 Inhibition with Cytotoxic Agents Does Not Enhance Cytotoxicity. PLoS One. 14(10):e0223555. https://doi.org/10.1371/journal.pone.0223555

2018

  1. Huang, J, Campian, JL, Gujar, A, Tsien, C, Ansstas, G, Tran, DD, DeWees, TA, Lockhart, AC, H, Kim, AH (2018). Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. Neuro-Onc. 138(1): 105-111. https://doi.org/10.1007/s11060-018-2775-y
  2. Liau, LM, Ashkan, K, Tran, DD, Campian, JL*, Trusheim, JE, Cobbs, CS, Heth, JA, Salacz, M, Taylor, S, D’Andre, SD, Iwamoto, FM, Dropcho, EJ, Moshel, YA, Walter, KA, Pillainayagam, CP, Aiken, R, Rekha, C, Goldlust, SA, Bota, DA, Duic, P, Grewal, J, Elinzano, H, Toms, SA, Lillehei, KO, Mikkelsen, T, Walbert, T, Abram, SR, Brenner, AJ, Brem, S, Ewend, MG, Khagi, S,  Portnow, J, Kim, LJ, Loudon, WG, Thompson, RC, Avigan, DE, Fink, KL, Geoffroy, FJ, Lindhorst, S, Lutzky, J, Sloan, AE, Schackert, G, Krex, D, Meisel, HJ, Wu, J, Davis, RP, Duma, C, Etame, AB, Mathieu, D, Kesari, S, Piccioni, D, Westphal, M, Baskin, DS, New, PZ, Lacroix, M, May, SA, Pluard, TJ, Tse, V, Green, RM, Villano, JL, Pearlman, M, Petrecca, K, Schulder, M, Taylor, LP, Maida, AE, Prins, RM, Cloughesy, TF, Mulholland, P, Bosch, ML (2018). First Results on Survival from a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma.  J Translat Med. 16(1):142-150. https://doi.org/10.1186/s12967-018-1507-6
    • Correction: J Transl Med. 16(1):179, 2018.

2017

  1. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017). Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 318(23):2306-2316. doi: 10.1001/jama.2017.18718.
  2. Mahlokozera T, Vellimana AK, Li T, Mao DD, Zohny ZS, Kim DH, Tran DD, Marcus DS, Fouke SJ, Campian JL, Dunn GP, Miller CA, Kim AH. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas. Neuro Oncol. 2017 Dec 13. doi: 10.1093/neuonc/nox232
  3. Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O’Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R, Sampson, JH (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): results of a randomized, double-blind, international phase 3 trial. Lancet Onc.18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X
    • Correspondence: Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O’Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors’ reply. Lancet Oncol. 18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2.
  4. Abadal, BK, Walsh, MA, Yachnis, AT, Tran, DD, Ghiaseddin, AP (2017). Eleven Month Progression–Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E–Mutated Glioblastoma, WHO Grade 4. JCO Precision Oncol. 1:1-5. https://doi.org/10.1200/po.17.00055

2016

  1. Lin, AL, White, M, Thomas, MM, Rich, K, Tsien, C, Fulton, R, Schmidt, R, Tran, DD*, Dahiya, S* (2016). Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol. 130:529. doi:10.1007/s11060-016-2247-1. *Senior/corresponding author.
  2. Gujar, AD, Le, S, Mao, DD, Dadey, DY, Turski , A, Sasaki, Y, Aum, D, Luo, J, Dahiya, S, Yuan, L, Rich, KM, Milbrandt, J, Hallahan, DE, Yano, H, Tran, DD, Kim, AH (2016). A NAD+-dependent Transcriptional Program Governs Self-Renewal and Radiation Resistance in Glioblastoma. Proc Natl Acad Sci USA. 113(51):E8247-E8256. https://doi.org/10.1073/pnas.1610921114
  3. Huang, J, Campian, JL, Tran, DD, Lockhart, AC, DeWees, TA, Tsien, CI, Kim, AH (2016). A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol. 128(2):259-66. https://doi.org/10.1007/s11060-016-2104-2
  4. Leuthardt, EC,Duan, C, Kim, MJ, Campian, JL, Kim, AH, Miller-Thomas, MM, Shimony, JS, Tran, DD (2016). Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier.Plos One. 11(2):e0148613. https://doi.org/10.1371/journal.pone.0148613 *Senior/corresponding author.
  5. Ansstas G and Tran DD (2016). Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series. Case Rep Neurol. 8(1)1-9. https://doi.org/10.1159/000442196

2015

  1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. Central Nervous System Cancers, Version 1. 2015. J Natl Compr Canc Netw. 13(10):1191-1202. https://doi.org/10.6004/jnccn.2015.0148
  2. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 314(23):2535-2543. https://doi.org/10.1001/jama.2015.16669
  3. Vlassenko, AG, McConathy, J, Couture, LE, Su, Y, Massoumzadeh, P, Leeds, HS, Chicoine, MR, Tran, DD, Huang, J, Dahiya, S, Marcus, DS, Fouke, SJ, Rich, KM, Raichle, ME, Benzinger, TLS (2015). Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Dis Markers. 2015:874904. https://doi.org/10.1155%2F2015%2F874904
  4. Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, Green J, Yellin MJ, Turner CD, Davis TA, Sampson JH. ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurg. 62, Suppl 1, clinical neurosurgery: 198-199. https://doi.org/10.1200/jco.2015.33.15_suppl.2009
  5. Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, Dacey RG, Achilefu S, Tran DD, Yano H, Kim AH (2015). A CDC20-APC/SOX signaling axis regulates human glioblastoma stem-like cells. Cell Reports. 11(11):1809-21. https://doi.org/10.1016/j.celrep.2015.05.027
  6. Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, Kim AH, Dunn G, Simpson JR, Robinson CG (2015). Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. Int J Radiat Oncol Biol Phys. 92(5):1000-1007. https://doi.org/10.1016/j.ijrobp.2015.04.005
  7. Speirs, CK, DeWees, TA, Simpson, JR, Robinson, CG, Tran, DD, Linette, G, Chicoine, MR, Dacey, RG, Rich, KM, Dowling, JL, Leuthardt, EC, Zipfel, GJ, Kim, AH, Huang, J (2015). Impact of 1p/19q codeletion and histology on the outcomes of anaplastic gliomas treated with radiotherapy and temozolomide. Int J Rad Onc Biol Phys 91(2):268-276. https://doi.org/10.1016/j.ijrobp.2014.10.027

2014

  1. Ammar H. Hawasli, Albert H. Kim, Gavin P. Dunn, David D. Tran and Eric C. Leuthardt (2014). Stereotactic Laser Ablation of High-Grade Gliomas. Neurosurg Focus 37(6):E1. https://doi.org/10.3171/2014.9.focus14471
  2. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran DD, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M (2014). Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 12(11):1517-1523. https://doi.org/10.6004/jnccn.2014.0151
  3. Badiyan, SN, Markovina, S, Simpson, JR, Robinson, CG, DeWees, T, Tran, DD, Linette, G, Jalalizadeh, R, Dacey, R, Rich, KM, Chicoine, MR, Dowling, JL, Leuthardt, EC, Zipfel, GJ, Kim, AH, Huang, J (2014). Radiotherapy Dose-Escalation for Glioblastoma Multiforme in the Era of Temozolomide. Int J Rad Onc Biol Phys 90(4):877-885. https://doi.org/10.1016/j.ijrobp.2014.07.014
  4. Tran, H, Luitel, K, Kim, M, Zhang, K, Longmore, G, Tran, DD (2014). Transient Snail1 Expression is Necessary for Metastatic Competence in Breast Cancer. Cancer Res. 74(21):6330-6340. * Senior/corresponding author. https://doi.org/10.1158/0008-5472.can-14-0923
  5. Mrugala, MM, Engelhard, HH, Tran, DD, Kew, Y, Cavaliere, R, Villano, JL, Bota, DA, Rudnick, J, Sumrall, AL, Zhu, JJ, Butowski, N (2014). Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe). Sem Oncol 41(Supp 6): S4-S13. https://doi.org/10.1053/j.seminoncol.2014.09.010
  6. Lacouture, ME, Davis, ME, Elzinga, G, Butowski, N, Tran, DD, Villano, JL, DiMeglio, L, Davies, AM, Wong, ET (2014). Characterization and Management of Dermatologic Adverse Events with the NovoTTF™-100A System, a Novel Anti-Mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma (rGB). Semin Oncol 41(Supp 4): S1-S14. https://doi.org/10.1053/j.seminoncol.2014.03.011
  7. Lin, A, Liu, J, Evans, J, Leuthardt, EC, Rich, KM, Dacey, RG, Dowling, JL, Kim, AH, Zipfel, GJ, Grubb, RL, Huang, J, Robinson, CG, Simpson, JR, Linette, GP, Chicoine, M, Tran, DD (2014). Codeletions at 1p and 19q predict for a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol 16(1): 123-130. *Senior/Corresponding author. https://doi.org/10.1093/neuonc/not142
  8. Hawasli, AH, Kim, AH, Dunn, GP, Tran, DD, Leuthardt, EC. Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus. 37(6):E1. https://doi.org/10.3171/2014.9.FOCUS14471
  9. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran DD, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M. (2013) Central Nervous System Cancers. J Natl Compr Canc Netw 11(9):1114-1151. https://doi.org/10.6004/jnccn.2013.0132
  10. Lin, M, Campian, J, Chicoine, MR, Huang, J, Tran, DD. “Neuro-Oncology” Chapter. Washington Manual, Oncology, 2nd Edition. Editors: Ramaswamy Govindan and Daniel Morgenstern. Lippincott William & Wilkins, 2014

2013 and Prior

  1. Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR (2013). Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 74(3):136-41. https://doi.org/10.1055/s-0033-1338262†
  2. Tran, DD, Corsa, CAS, Biswas, H, Aft, RL, Longmore, GD (2011). Temporal and Spatial cooperation of Snail1 and Twist1 during Epithelial-Mesenchymal Transition predicts for human breast cancer recurrence.Mol Cancer Res 9(12):1644-1657. *D. Tran: Corresponding author. (Free Featured Article). https://doi.org/10.1158/1541-7786.mcr-11-0371
    1. Editorial highlight: MCR (2011) 9:1571.
  3. Wang-Gillam, A, Tran, DD. “Peritoneal Carcinomatosis.”  DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology Review, 2nd Edition. Editor: Ramaswamy Govindan.  Lippincott William & Wilkins, 2009.  465-473 (3rd edition 2012)
  4. Tran, DD. “Imatinib and Nilotinib.” Oncology Chemotherapy and Supportive Care Medications.  Editors: Ramaswamy Govindan and Sara K. Maier. Lippincott William & Wilkins, 2010
  5. Yu, L, Malureanu, L, Karthibabu, J, Tran, DD, Lindquist, L, Bram, RJ (2009). CAML loss causes anaphase failure and chromosome missegregation. Cell Cycle 8(6)940-949. https://doi.org/10.4161%2Fcc.8.6.7948
  6. Yuan, X, Yao, J, Norris, D, Tran, DD, Bram, RJ, Chen, G, Luscher, B (2008). Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABAA. Mol. Cell. Neurosci. 38(2)277-289. https://doi.org/10.1016%2Fj.mcn.2008.03.002
  7. Tran, DD, Heckman, K, McKean, D, Deursen, JV, Bram, RJ (2005). CAML interacts with p56Lck and is required for T cell development. Immunity 23(8)139-152. https://doi.org/10.1016/j.immuni.2005.06.006
  8. Trushina, E, Dyer, RB, Badger, II JD, Ure, D, Eide, L, Tran, DD, Vrieze, BT, Legendre-Guillemin, V, McPherson, PS, Mandavilli, BS, Houten, BV, Zeitlin, S, McNiven, M, Aebersold, R, Hayden, M, Parisi, JE, Seeberg, E, Dragatsis, I, Doyle, K, Bender, A, Chacko, C, McMurray, CT (2004). Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Cell. Biol. 24(18):8195-8209. https://doi.org/10.1128/mcb.24.18.8195-8209.2004
  9. Tran, DD, Russell, H, Sutor, SL, Deursen, JV, Bram, RJ (2003). CAML is required for efficient EGF receptor recycling. Developmental Cell 5(2):245-256. https://doi.org/10.1016/S1534-5807(03)00207-7
  10. Horne, MC, Donaldson, KL, Goolsby, GL, Tran, DD, Mulheisen, M, Hell, JW, Wahl, AF (1997). Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 272: 12650-12661. https://doi.org/10.1074/jbc.272.19.12650
  11. Horne, MC, Goolsby, GL, Donaldson, KL, Tran, D, Neubauer, M, Wahl, AF. (1996). Cyclin G1 and Cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem. 271: 6050-6061. https://doi.org/10.1074/jbc.271.11.6050

Issued and Pending Patents

  1. Tran, D.D., Chen, D. “Methods to induce programmed necrotic cell death in cancer as a cytotoxic therapy and immunotherapy.” University of Southern California. Provisional Application. US63/657,384, 2024.
  2. Tran, D.D., Le, S, and Thai, N. “Direct conversion of human mesenchymal stem cells to human cardiomyocytes.”  University of Florida.  Provisional Application filed June 2022, Serial No. 63/352,178 and 63/351,108. PCT/US2023/068115, filed June 8, 2023. Published December 14, 2023: WO 2023/240176
  3. Tran, D.D. and Chen, D “Methods and compositions for determining susceptibility to treatment with checkpoint inhibitors.” University of Florida. PCT filed February 2022, Serial No 63/172862
  4. Tran, D.D. “Master regulators of breast cancer metastasis.” University of Florida. US Provisional Application filed March 2020, Serial No. 62/985,785
  5. Tran, D.D. and Le, S. “Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells.” University of Florida. US Provisional Application filed December 2019: Serial No. 62/952,725; PCT/US2020/066557.
  6. Tran, D.D. and Chen, D. “Methods for reducing viability of cancer cells by activation of the STING pathway with TTFields.” University of Florida. U.S. Provisional Application filed November 2019. PCT filed April 2020: Serial No. 16/673,246 Page 18 of 37
  7. Tran, D.D., Chen, D, and Le, S. “Inhibiting prostaglandin e receptor 3 resensitizes resistant cells to TTFields and prevents cells from developing resistance to TTFields.” University of Florida. U.S. Provisional Application filed March 2019. PCT filed October 2019: Serial No. 62/849,535
  8. Zolotukhin, S, Tran, D.D., and Kondratov, O. “AAV capsid variants targeting human glioblastoma stem-like cells.” University of Florida. U.S. Provisional Application filed August 2019. PCT filed August 2020: Serial No. 62/884,716
    o Exclusive license to Lacerta Therapeutics, December 2019.
  9. Tran, D.D., and Le, S. “Core master regulators of glioblastoma stem cells.” University of Florida. US
    Provisional Patent Application filed February 2019. PCT February 2020: Serial No. 62/802,554
    o Selected one of the 25 finalists globally for the 2019 Brain Race –The Center for Advancing Innovation, Bethesda MD
    o Exclusive license to Lacerta Therapeutics, July 2021
  10. Tran, D.D., and Le, S “Methods for targeted treatment and prediction of patient survival in cancer.” University of Florida. US Provisional Patent Application filed February 2019: Serial No. 62/802,653
  11. Tran, D.D., and Le, S. “Methods for cancer screening and monitoring by cancer master regulators markers in liquid biopsy.” University of Florida. US Provisional Patent Application filed February 2019: Serial No. 62/802,620
  12. Le, S and Tran D.D. “Novel factors for cell fate conversions.” University of Florida. 2017: UF#16818
  13. Tran, D.D., and Le, S. “Direct conversion of brain cancer cells into antigen-presenting immune cells.” University of Florida. US Provisional Patent Application filed June 2017: Serial No. 62/522,887
  14. Tran, D.D., and Le, S. “Core Master Regulators of Glioblastoma Stem Cells.” University of Florida. Provisional filed in 2017. PCT filed May 2018: US/International Patent Application Serial No. 62/586,655. Published November 2018
    o Selected one of the 25 finalists globally for the 2019 Brain Race –The Center for Advancing Innovation, Bethesda MD
    o Exclusive license to Lacerta Therapeutics, July 2021
    o Issued 2023
  15. Tran, D.D., and Le, S. “Targeting mechanisms of immune escape by brain cancer cells to synergize with existing cancer immunotherapies.” University of Florida. U.S. Provisional Patent Application filed June 2017: Serial No. 62/522,882
  16. Tran D.D. and Le, S. “GeneRep and nSCORE: Method and apparatus for improved determination of node influence in a network.” University of Florida. Provisional filed 2016. PCT filed October 2017: US/International Patent Application Serial No. 62/408,045. Published April 2018.
    o Issued 2023
  17. Tran, D.D. “Chemotherapeutic resensitization of disseminated cancer stem cells through reactivation by p38 inhibition and IL-6 inhibition – chemotherapeutic methods.” University of Florida. Provisional filed in 2016. PCT filed February 2017: US/International Patent Application Serial No. 62/301,210. Published August 2017.
    o Issued 2022
  18. Tran, D.D. and Le, S. “A molecular cell diary system.” University of Florida. Provisional filed 2016. PCT filed February 2017: US/International Patent Application Serial No. 62/301,813.
    o Issued 2022